maintain hold rate follow result solid
perform us pharmaci wholesal off-set tepid retail sale
on-going overarch challeng expect head wind persist
reimburs could even intensifi bit transform
cost manag program help provid off-set expect
partnership digit effort drive top line margin growth
time addit trend remain solid allow on-going investment/
capit deploy maintain hold target ep
result touch ahead revenu came top
estim weaker expect perform retail pharmaci
vs strhe off-set slight beat wholesal
vs strhe retail pharmaci usa revenu
in-lin script volum half
script growth show solid improv vs
higher revenue/script provid off-set specialti growth brand inflat
market share fell bp tie store optim program
exit year market share time high retail
busi remain challeng retail sale ss sale
fell larg driven de-emphasi tobacco ex tobacco
bp half show solid improv vs
sg higher think tie elev
invest level prior year legal accruals/settl adjust ep
aid lower share count come four cent ahead
compani also provid adjust ep guidanc roughli flat rang
/- rel guidanc reflect impact lower bonu
payout higher tax rate share repurchas
suggest oper growth
compani continu make headway transform
manag program rais annual cost save target greater
greater manag renam
program invest grow make chang across number
area includ mandat competit bid extern consult
tie contract outcom also remain focus optim
organiz structur select reduct support offic
addit restructur alreadi underway
tr target
wholesal segment final real estat footprint review complet expect invest
across sap pharmaci system upgrad portfolio sap on-going
digit side microsoft cloud migrat track walgreen mobil app download
yoy digit initi sale grew nearli yoy
partnership expans effort beauti walgreen continu expand
portfolio partnership effort drive foot traffic grow script volum creat health
well hub given posit feedback announc expans current pilot
kr nr includ expand kroger express locat walgreen store
sell own health beauti product store compani also roll
beauti haul key locat introduc new beauti brand septemb
addit focu well primari care high compani ad partnership jenni
craig privat includ launch weight loss manag center locat
given specialti growth also taken minor interest shield solut privat
specialti pharmaci provid enter collabor rxadvanc
buy expect medicaid growth area focu near/intermedi term also view
medic adher program refil favor given potenti impact
clinic outcom compani recent announc multi-year agreement unitedhealth
buy creat co-brand plan exclus prefer
retail pharmaci wholesal retail pharmaci revenu
came estim oper condit remain challeng lower
ss retail sale fell total sale cc boot uk result pharmaci
wholesal remain strong revenu come ahead ss sale
increas cc strength emerg market
opportun cffo came estim
tie hand head wind cost save invest partnership invest
compani made share repurchas importantli move
work capit program cost manag program govern compani see
meaning opportun drive improv work capit especi inventori next sever
year adjust full year estim revenu vs prior
adjust ep vs prior maintain hold rate price target
page
revenu
revenu
revenu
net incom
non-gaap add back tax
adjust net incom
page
inc global leader pharmaceut servic industri us
store sizabl wholesale/distribut network countri compani largest retail
pharmaci unit state retail pharmaci usa divis gener total
compani revenu remain sale come retail intern pharmaci
wholesal
continu view trend pharmaceut servic solid given age popul util
growth increas specialti demand expect reimbursement/th impact gener remain
remain headwind fo forese futur believ portfolio strateg partnership
collabor labcorp demonstr valu compani scale/
capabl provid on-going volum tailwind reason optim
challeng exist retail pharmaci busi continu see margin pressur tie sever
factor rate price pressur payer contract increasingli difficult overal retail
valuat risk
hold rate price target base stock trade adjust cash
ep modestli ahead current multipl continu see solid underli trend
pharmaceut servic view compani scale key differenti like compani free
cash flow gener view risk/reward balanc given us pharmaci margin pressur
like linger difficult retail environ upsid risk price target includ stronger core
trend dissip reimburs pressur aggress capit deploy downsid risk
includ increas price pressur addit retail competit
compani mention note
david macdonald herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express
specif recommend report
